Address Concerns About The Safety Of BOTOX

The popularity of Botox ® for use in the cosmetic treatment of facial wrinkles, known as Botox ® cosmetic, it is because of its simplicity and considerable efficiency. It has become so familiar with popular culture and media, communication, his name is often used as a noun and a verb. (This is both disturbing and discouraged by the manufacturer) recent negative publicity for its use in children with neuromuscular diseases have not accurately represented his safety record in cosmetic applications. To alleviate the concerns of potential patients, it is useful to consider some factual information about the drug to dispel any confusion created by recent media reports.

Botox Cosmetic ® (botulinum toxin type A) is produced and sold by the company owner, Allergan, based in Irvine, California. It's been 18 years since it was originally approved to treat blepharospasm (eyelid spasms excessive) and 6 years since its approval for the cosmetic treatment of the vertical lines between the eyebrows. Several million patients have been treated worldwide cosmetics and the manufacturer indicates that more than 13 million doses have been given since 2002. According to the American Society of Plastic Surgery, Botox ® Cosmetic is the No. 1 cosmetic procedure done in the United States since 2002 with more than 3 million doses given in 2006. With over 3000 published medical reports and a large number of clinical trials reviewed Welther people is a security information available. Side effects of Botox, despite the large amount of doses, and patients are allergic rare.Any very aesthetic true to its use have not been reported.

To date, there has never been a single reported deaths associated with its use either.

These aesthetic experiences can be compared with media reports in which its use has been in limb spasticity, which is not an application approved by the FDA. These is the use of neuromuscular significantly higher doses (100 times) given in relation to what is given in doses and injected cosmetic patients who are often sick and weakened by their disease. These two populations of patients and their indications, is just not the same. The FDA appears to recognize these differences and have issued any interruption of its use for any application with the health care provider right now.

The exact representation of safety data on BOTOX ® Cosmetic should provide comfort to patients who receive regular beauty treatments, or those proposed in the near future.